— Affymetrix Announces Preliminary Fourth Quarter 2013 Revenue of Approximately $91 Million —

  — Affymetrix Announces Preliminary Fourth Quarter 2013 Revenue of
  Approximately $91 Million —

Business Wire

SANTA CLARA, Calif. -- January 7, 2014

Affymetrix, Inc., (NASDAQ: AFFX) today announced that based on preliminary,
unaudited financial data, the Company expects total revenue for the fourth
quarter of 2013 will be approximately $91 million, including a one-time
licensing payment of $5.3 million from a diagnostic partner. For fiscal 2013,
the Company expects total revenue of approximately $329 million.

“In 2013 we executed effectively against our three phase strategic plan and we
exited the year as a much stronger Company,” said Dr. Frank Witney, president
and chief executive officer. “Over the last 12 months we improved our
business’s performance, significantly reduced our senior debt and increased
our overall cash balance.”

This information is being released in advance of the 32nd Annual JP Morgan
Healthcare Conference in San Francisco, California. The company will present
on January 16, 2014. The live webcast is scheduled to begin at 8:00 AM Pacific
Time and will feature a presentation by Dr. Witney.

Additionally, Affymetrix’s management team will host a conference call on
Wednesday February 5, 2014 at 2:00 p.m. PT. A live webcast can be accessed by
visiting the Investor Relations section of the Company's website at
www.affymetrix.com. In addition, investors and other interested parties can
listen by dialing domestic: (877) 407-4812, international: (201) 689-8345.

A replay of this call will be available from 5:00pm PT on Wednesday February
5, 2014 until 8:00pm PT on February 12, 2014 at the following numbers:
877-660-6853 (domestic), 201-612-7415 (international). The pass code to access
the conference call is 13574000. An archived webcast of the conference call
will be available under the investor relations section of the company's
website at www.affymetrix.com.

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic,
and biotechnology companies, as well as leading academic, government, and
nonprofit research institutes. More than 2,300 systems have been shipped
around the world and more than 48,000 peer-reviewed papers have been published
using the technology. Affymetrix is headquartered in Santa Clara, California,
and has manufacturing facilities in Cleveland, Ohio, San Diego, California,
Singapore and Vienna, Austria. The Company has about 1,100 employees worldwide
and maintains sales and distribution operations across Europe, Asia and Latin
America.

Forward-Looking Statements

Affymetrix has not filed its Form 10-K for fiscal 2013. As a result, all
financial results described in this press release should be considered
preliminary, and are subject to change to reflect any necessary corrections or
adjustments, or changes in accounting estimates, that are identified prior to
the time the company is in a position to complete these filings.

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix's "expectations," "beliefs," "hopes," "intentions," "strategies" or
the like. Such statements are subject to risks and uncertainties that could
cause actual results to differ materially for Affymetrix from those projected,
including, but not limited to: strategic benefits and costs savings or other
synergies of the acquisition of eBioscience in a cost-effective manner while
minimizing the disruption to its business; risks that eBioscience’s future
performance may not be consistent with its historical performance; risks
relating to Affymetrix's ability to make scheduled payments of the principal
of, to pay interest on or to refinance its indebtedness; risks relating to
Affymetrix's ability to successfully develop and commercialize new products,
including its ability to successfully develop and commercialize novel
molecular solutions based on eBioscience’s portfolio of reagents; risks
relating to past and future acquisitions, including the ability of Affymetrix
to successfully integrate such acquisitions into its existing business; risks
of Affymetrix's ability to achieve and sustain higher levels of revenue,
higher gross margins and reduced operating expenses; risks relating to
Affymetrix’s ability to generate cash after interest and principal payments;
uncertainties relating to technological approaches; risks associated with
manufacturing and product development; personnel retention; uncertainties
relating to cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties relating to sole-source suppliers;
uncertainties relating to FDA and other regulatory approvals; competition;
risks relating to intellectual property of others and the uncertainties of
patent protection and litigation. These and other risk factors are discussed
in Affymetrix's Quarterly Report on Form 10-Q for the quarter ended September
30, 2013, and other SEC reports. Affymetrix expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
Affymetrix's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.

PLEASE NOTE:

Affymetrix, the Affymetrix logo, GeneChip, and all other trademarks are the
property of Affymetrix, Inc.

Contact:

Affymetrix, Inc.
Doug Farrell, 408-731-5285
Vice President of Investor Relations
 
Press spacebar to pause and continue. Press esc to stop.